Table 3 Summary of the study outcomes
|  | Period A (1st July 2017–30th June 2018) | Period B (1st July 2018–30th June 2019) | p-value |
|---|---|---|---|
Patients admitted for at least 48Â h, n | 709 | 698 | 0.67 |
Occurrence of MDRO infections | Â | Â | Â |
 Total MDRO isolates, n | 53 | 39 | 0.22 |
 Carbapenem-resistant Acinetobacter baumannii, n | 0 | 1 | 0.25 |
 Carbapenem-resistant Klebsiella pneumoniae, n | 7 | 6 | 0.42 |
 Carbapenem-resistant Pseudomonas aeruginosa, n | 7 | 1 |  < 0.01 |
 Clostridioides difficile, n | 2 | 0 | 0.10 |
 ESBL-producing enteric Gram-negative bacteria, n | 18 | 14 | 0.59 |
 Methicillin-resistant Staphylococcus aureus, n | 19 | 16 | 0.37 |
 Vancomycin-resistant enterococci, n | 2 | 1 | 0.60 |
Length of in-hospital stay, mean | 9.46 | 9.8 | 0.60 |
All-cause in-hospital mortality, n (%) | 19 (2.68) | 15 (2.15) | 0.50 |
Antibiotic consumption | Â | Â | Â |
 Carbapenems, DDDs*100 PDs, mean | 4.53 | 1.51 | 0.01 |
 Daptomycin, DDDs*100 PDs, mean | 2.64 | 0.05 |  < 0.01 |
 Clindamycin, DDDs*100 PDs, mean | 0.33 | 3.34 |  < 0.01 |
Antibiotic costs, euros | 54,876.44 | 21,777.26 | 0.03 |